C

Caidya

Global CRO delivering end-to-end clinical development

Investigator Contracts Lead - Insourced to MNC

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's, Master's, JD, Certification
China
In Person
Contract Management

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science degree in a related field is required; an advanced degree is preferred.
  • Paralegal certification or a Juris Doctor is preferred.
  • At least 3 years of contracts-related experience is essential; clinical research, contracts, or related experience in a team-oriented environment is preferred, and CRO or pharmaceutical experience is strongly preferred.
  • A strong understanding of contracting principles and requirements is required.
  • Familiarity with budget development, benchmarking practices, and fair market value principles is required.
  • Proficiency in general and regionally specific contract fundamentals, with the ability to apply this knowledge to contract drafting, review, negotiation, and amendment processes.
  • Ability to handle multiple tasks and meet deadlines in a dynamic environment.
  • Understanding of clinical trial processes across Phases II–IV and ICH Good Clinical Practice, and ability to interact effectively with investigative site personnel.
  • Organizational skills and attention to detail, including the ability to handle multiple tasks effectively.
  • Ability to identify and understand site contract and budget issues early, communicate them concisely to internal and client project teams, draft responses to resolve them, problem-solve, and work independently using initiative.
  • Sound judgment and willingness to make timely decisions.
  • Ability to prioritize and plan work, use time efficiently, develop realistic action plans, and learn relevant new skills.
  • Proficiency with Windows, Microsoft Word, Excel, and PowerPoint.
  • Exceptional written and oral English communication skills; proficiency in another language is advantageous.
  • Strong personal interaction skills.
Responsibilities
  • Act as Contract Lead for assigned countries and regions, participate in kick-off meetings and sponsor calls, provide clients with procedural and legal guidance, and advise on study updates and ways to expedite site contract execution.
  • Forecast intermediate Clinical Contract steps and oversee execution to achieve contractual milestones.
  • Manage Contracts Specialists and other staff negotiating site contracts on the project, and ensure they have access to applicable study systems and folders, including Egnyte, D365, eTMF, and study-startup systems.
  • Create study-specific contract templates for assigned countries, by drafting them directly or collaborating with assigned contract negotiators.
  • Work with the Project Manager and Sponsor to develop contract negotiation guidelines and parameters, escalation pathways, and sponsor-specific signature requirements.
  • Work with the Project Manager, Grants Administration, Sponsor, and local Country Experts to develop country-specific site budget templates, negotiation benchmarks, escalation procedures, and fair market value assessment procedures.
  • Forecast site contract execution dates and communicate timelines to stakeholders to support timely site activation; oversee site contract and budget status entries in applicable tracking systems.
  • Collaborate with contract negotiators to resolve site contract and budget negotiation impasses, including directly negotiating contracts and budgets with study sites when appropriate.
  • Conduct fair market value assessments of budget items outside negotiation benchmarks, facilitating Sponsor approval or providing direct approval when authorized.
  • Serve as an internal escalation point to resolve legal-language negotiations and approve contract terms when authorized.
  • Maintain and update country-specific contract templates in the Clinical Contracts CTA template repository.
  • Support development and creation of contracts-related departmental intelligence tools.
  • Mentor Clinical Contracts team members on complex contract issues and serve as a contracts subject-matter expert within the department and across departments.
  • Conduct training when called upon.
Desired Qualifications
  • Experience in clinical research, contracts, or a related area in a team-oriented environment.
  • Experience in a CRO or pharmaceutical setting.
  • An advanced degree.
  • Legal education, such as paralegal certification or a Juris Doctor.
  • Experience with industry benchmarking tools such as GrantPlan or GrantsManager.
  • Proficiency in a language in addition to English.

About the company

Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceutical and medical device companies. It covers the full lifecycle from pre-IND strategy and early-phase development through late-stage trials, regulatory submissions, and post-marketing surveillance, delivered via flexible models like standalone projects, full-service partnerships, and functional service provider arrangements, supported by its Clarity data platform that offers near real-time trial visibility and compatibility with Medidata Rave and Veeva. Its competitive edge comes from the merged legacy of Clinipace and dMed Global, strong leadership under Dr. Lingshi Tan, a broad global footprint including North America and China, and an emphasis on data-driven, transparent trial delivery. The goal is to help clients bring therapies to market efficiently and compliantly through high-quality, scalable trial execution across global programs.

Company Size

201-500

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$322.2M

Headquarters

Morrisville, North Carolina

Founded

2003

Get referred to Caidya

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 NMPA accepted partner MediLink's Tam-Peli NDA, validating China execution.
  • Caidya’s APAC-heavy model fits sponsors needing China speed and regulatory navigation.
  • Rubicon’s $165 million 2025 growth capital still funds expansion and integration.

What critics are saying

  • Combining Caidya and Simbec-Orion creates integration failure risk through 2026-2027.
  • CRO rivals Fortrea, ICON, and Medpace outspend Caidya on scale and technology.
  • Failed integration traps Caidya as a subscale CRO and forces retrenchment.

What makes Caidya unique

  • June 30, 2026 deal with Simbec-Orion adds Phase I clinical pharmacology to Caidya.
  • Barbara Lopez Kunz now runs a CRO spanning Europe, Americas, APAC, and China.
  • Michael Clay’s February 2026 COO hire deepens global delivery across 60 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Business Wire
Jul 1st, 2026
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution....

Associated Press
Feb 17th, 2026
Caidya appoints Michael Clay as COO to strengthen global clinical trial operations across Asia-Pacific

Caidya, a global clinical research organisation, has appointed Michael Clay as chief operating officer. Clay will oversee global operational delivery, client engagement and execution strategy across the US, Europe and Asia-Pacific. Clay brings extensive experience leading global clinical programmes across more than 60 countries, with particular expertise in Asia-Pacific operations. Most recently, he served as senior vice president of Global Project Delivery at Fortrea, where he managed over 500 global clinical trials. The appointment strengthens Caidya's operational capabilities, particularly in China and the broader APAC region. Caidya operates in more than 20 countries and conducts studies across over 50 countries, focusing on complex therapeutic areas including oncology, haematology and rare diseases.

Business Wire
Jan 16th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.

Business Wire
Jan 13th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya announces $165 million strategic growth investment from Rubicon Founders.

FinSMEs
Jul 10th, 2021
dMed-Clinipace Closes US$50M Series C+ Financing

dMed-Clinipace, a Shangai, China- and Morrisville, NC-based global full-service Clinical Contract Research Organization (CRO), closed a US$50m Series C+ financing. The round was led by Springhill Fund, with participation from funds managed by Rock Springs Capital and Superstring Capital. They joined Series C lead investor Fidelity Management and Research Company LLC as well as other new […]